We previously developed and validated a caspase-3-specific radiotracer, 18F-ICMT-11, for PET imaging of tumour apoptosis in several pre-clinical tumour models, and have also demonstrated safe clinical profiles of the radiotracer in phase I/II trials [14–19]. This evidence concerns the gene CASP3 and neoplasm.